Nuvectra Corporation (NASDAQ:NVTR) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01

Effective June 19, 2017, Nuvectra Corporation (Nuvectra) entered
into a Second Amendment to the Development Agreement (the
Amendment) with Aleva Neurotherapeutics, S.A., a Swiss share
company (Aleva) to amend the Development Agreement between Aleva
and Nuvectra, dated January 29, 2016 (the Development Agreement).
Under the terms of the Amendment, Aleva and Nuvectra agreed to
modify the payment schedule and the timing of certain payments as
set forth on Exhibit A of the Development Agreement and
that any additional work performed by Nuvectra will be paid on a
monthly basis.

The foregoing description is not complete and is qualified in its
entirety by reference to the full text of the Amendment to the
Development Agreement, which is filed as Exhibit 10.1 to this
Current Report and incorporated by reference into this Item 1.01.

(d)Exhibits.

Nuvectra Corp Exhibit
EX-10.1 2 ex10-1.htm EXHIBIT 10.1 ex10-1.htm Exhibit 10.1   SECOND AMENDMENT TO THE DEVELOPMENT AGREEMENT   This Second Amendment (the “Amendment No. 2”) dated as of June 19,…
To view the full exhibit click here
About Nuvectra Corporation (NASDAQ:NVTR)

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company’s neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).